China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai Escugen, aimed at advancing the research, development, and manufacturing of antibody-drug conjugates (ADCs). The collaboration extends from late clinical development through to the commercialization phase, with financial details undisclosed.
Leveraging Tot Bio’s Expertise in ADC Development
Tot Bio will utilize its comprehensive expertise in the entire value chain of drug development to support Escugen’s ADC programs. This includes leveraging the commercial advantages of ADC antibodies, raw materials, and formulations produced at the same site, as well as a quality system verified by regulatory authorities. The partnership will fully support key clinical batch production, process characterization, and process validation (PC/PV), market application, and commercial production supply for Escugen’s ADC programs across China, America, and Europe.
Expanding the Reach of ADCs in Global Markets
This partnership signifies a significant step forward in the global ADC landscape, combining Tot Bio’s established capabilities with Escugen’s innovative approach to drug development. The collaboration is poised to enhance the development and commercialization of ADCs, offering potential new treatment options for patients worldwide.-Fineline Info & Tech
